Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid
- PMID: 6707192
- DOI: 10.1210/jcem-58-5-889
Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid
Abstract
This study was conducted to compare the diagnostic and prognostic values of calcitonin (CT) and carcinoembryonic antigen (CEA) measurements in patients with medullary carcinoma of the thyroid (MCT). Plasma CEA, basal CT (BCT), and peak CT (PCT) levels after pentagastrin stimulation were determined in 15 patients with occult familial MCT before treatment. CEA was elevated in 11 patients (73%), BCT in 8 patients (53%), and PCT in all patients. The prognostic values of serial CEA and BCT determinations were studied in 24 other MCT patients followed for a period of 1.5-8 yr. These patients were divided into 2 groups; group I consisted of 11 patients with normal serial CEA levels, and group II consisted of 13 patients with persistently elevated CEA levels. In group I, 2 patients (18%) developed metastases compared with 10 patients (77%) in group II (P less than 0.001). Elevated BCT levels were found in all patients with metastases as well as in 63% of patients with no evidence of disease. When CEA time curves were studied, three patterns could be identified: 1) a steep slope with rapidly rising CEA levels in patients with rapidly progressive disease, 2) a flat slope in patients with no metastasis or nonprogressive disease, and 3) an intermediate type of slope in patients with slowly progressive disease. Slope analysis of BCT time curves was not done because of marked fluctuations in BCT levels. PCT after pentagastrin stimulation remains the best diagnostic marker for MCT. However, CEA may be a better prognostic indicator, as it discriminated more efficiently between patients with and without metastasis. Slope analysis of CEA time curve and calculation of the doubling time are recommended, as they correlated well with the course of the disease.
Similar articles
-
Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma.Cancer. 1984 Jan 15;53(2):278-85. doi: 10.1002/1097-0142(19840115)53:2<278::aid-cncr2820530216>3.0.co;2-z. Cancer. 1984. PMID: 6690009
-
[Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma].Gan No Rinsho. 1986 Oct;32(12):1519-24. Gan No Rinsho. 1986. PMID: 3783976 Japanese.
-
[Tumours markers. Calcitonin and carcinoembryonic antigen in medullary carcinoma of the thyroid (author's transl)].Presse Med (1893). 1979 Dec 10;8(48):3947-50. Presse Med (1893). 1979. PMID: 530945 French.
-
Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: a comparative study.Endocrinol Jpn. 1976 Dec;23(6):505-10. doi: 10.1507/endocrj1954.23.505. Endocrinol Jpn. 1976. PMID: 1022524
-
Demonstration of calcitonin and carcinoembryonic antigen (CEA) in medullary carcinoma of the thyroid (MCT) by immunoperoxidase technique.Histopathology. 1979 Nov;3(6):503-10. doi: 10.1111/j.1365-2559.1979.tb03031.x. Histopathology. 1979. PMID: 389771
Cited by
-
The utility of some modern techniques in understanding thyroid pathology.Endocr Pathol. 1990 Jun;1(2):68-84. doi: 10.1007/BF02915622. Endocr Pathol. 1990. PMID: 32138436 Review.
-
Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.J Cancer Res Clin Oncol. 1992;118(8):629-34. doi: 10.1007/BF01211810. J Cancer Res Clin Oncol. 1992. PMID: 1355485 Free PMC article.
-
Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: an unusual clinical coexistence.J Endocrinol Invest. 2001 Dec;24(11):892-6. doi: 10.1007/BF03343948. J Endocrinol Invest. 2001. PMID: 11817715
-
Secretion of calcitonin and carcinoembryonic antigen in long-term organ culture of human medullary thyroid carcinoma: biochemical and immunocytochemical studies.Klin Wochenschr. 1985 Mar 1;63(5):205-10. doi: 10.1007/BF01731170. Klin Wochenschr. 1985. PMID: 3990162
-
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.Front Endocrinol (Lausanne). 2020 Aug 7;11:490. doi: 10.3389/fendo.2020.00490. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32849281 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical